Free Trial
NASDAQ:ALRN

Aileron Therapeutics Q2 2024 Earnings Report

Aileron Therapeutics EPS Results

Actual EPS
-$0.45
Consensus EPS
-$0.25
Beat/Miss
Missed by -$0.20
One Year Ago EPS
N/A

Aileron Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aileron Therapeutics Announcement Details

Quarter
Q2 2024
Time
After Market Closes
Conference Call Date
Wednesday, August 14, 2024
Conference Call Time
4:15PM ET

Aileron Therapeutics Earnings Headlines

Aileron Therapeutics Rebrands As Rein Therapeutics
The IRS Loophole That Lets You Own Gold Tax-Free
What if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? No gimmicks. No shady tricks. Just a powerful IRS-approved loophole that most Americans have never heard of. It's called a Self-Directed Gold IRA, and it's quietly becoming the go-to wealth protection strategy for people who see the writing on the wall. When you take the next step, you could qualify for up to $10,000 in FREE GOLD & SILVER with your purchase of a qualified account.
See More Aileron Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aileron Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aileron Therapeutics and other key companies, straight to your email.

About Aileron Therapeutics

Aileron Therapeutics (NASDAQ:ALRN), a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.

View Aileron Therapeutics Profile

More Earnings Resources from MarketBeat